Drug Type siRNA |
Synonyms PF 4523655, PF-04523655, PF-655 + [5] |
Target |
Mechanism Redd1 inhibitors(DNA damage-inducible transcript 4 protein inhibitors), RNA interference |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Wet Macular Degeneration | Phase 2 | - | - | 06 Apr 2010 |
Age Related Macular Degeneration | Phase 2 | US | 01 Nov 2009 | |
Age Related Macular Degeneration | Phase 2 | US | 01 Nov 2009 | |
Age Related Macular Degeneration | Phase 2 | AT | 01 Nov 2009 | |
Age Related Macular Degeneration | Phase 2 | AT | 01 Nov 2009 | |
Age Related Macular Degeneration | Phase 2 | DK | 01 Nov 2009 | |
Age Related Macular Degeneration | Phase 2 | DK | 01 Nov 2009 | |
Age Related Macular Degeneration | Phase 2 | HK | 01 Nov 2009 | |
Age Related Macular Degeneration | Phase 2 | HK | 01 Nov 2009 | |
Age Related Macular Degeneration | Phase 2 | IN | 01 Nov 2009 |
Not Applicable | Diabetic macular oedema RTP801 gene | 184 | PF-04523655 0.4mg | ykntnnofiz(wbjxknlzrv) = ldfegccvcy bwrbfwjmec (ehqqqzzyro, -3.3 to 3.0) | Positive | 23 Oct 2011 | |
PF-04523655 1.0mg | ykntnnofiz(wbjxknlzrv) = vtvbglcxak bwrbfwjmec (ehqqqzzyro, -1.4 to 5.0) | ||||||
Phase 1 | 13 | kvjjsoawnr(iofbvczpvz) = mlbagjxhxt szbavtnrri (pbgabhlhis, +12.25) View more | - | 01 Apr 2009 |